Psoriasis and metabolic syndrome: Is peroxisome proliferator-activated receptor-γ part of the missing link?

European Journal of Dermatology

Volumn 22, Issue 5, 2012, Pages 622-628

  Hegazy, Rehab A ^a   Abdel Hay, Rania M ^a   Shaker, Olfat ^a   Sayed, Safinaz S ^a   Abdel Halim, Dalia A ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Immunohistochemistry; Metabolic syndrome; PPAR?; Psoriasis; Western blot

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PROTEIN EXPRESSION; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX SCORE; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SKIN BIOPSY; SMOKING; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANALYSIS OF VARIANCE; BLOOD GLUCOSE; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIPOPROTEINS, HDL; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; PPAR GAMMA; PSORIASIS; ROC CURVE; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 84868290052     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2012.1789     Document Type: Article

References (41)

1. Azfar RS, Gelfand JM. Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol 2008; 20: 416-22.
2. Alsufyani MA, Golant AK, Lebwohl M. Psoriasis and the metabolic syndrome. Dermatol Ther 2010 Mar-Apr;23(2):137-43.
3. Gisondi P, Ferrazzi A, Girolomoni G. Metabolic comorbidities and psoriasis. Acta Dermatovenerol Croat 2010; 18: 297-304.
4. Rosen ED, Spiegelman BM. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001; 276: 37731-4.
5. Mössner R, Kaiser R, Matern P, et al. Variations in the genes encoding the peroxisome proliferator-activated receptors alpha and gamma in psoriasis. Arch Dermatol Res 2004; 296: 1-5.
6. Michalik L, Wahli W. Peroxisome proliferator-activated receptors (PPARs) in skin health, repair and disease. Biochim Biophys Acta 2007; 771: 991-8.
7. Oyekan A. PPARs and their effects on the cardiovascular system. Clin Exp Hypertens 2011; 33: 287-93.
8. Tanaka T, Masuzaki H, Hosoda K, Nakao K. Critical roles of PPARgamma in every aspect of the metabolic syndrome. Nihon Rinsho 2010; 68: 203-9.
9. Halvorsen B, Heggen E, Ueland T, et al. Treatment with the PPARgamma agonist rosiglitazone downregulates interleukin-1 receptor antagonist in individuals with metabolic syndrome. Eur J Endocrinol 2010; 162: 267-73.
10. International Diabetes Federation consensus worldwide definition of the metabolic syndrome (2006) (WWW document) URL http://www.idf.org/webdata/docs/MetSyndrome_FINAL.pdf. [accessed July 2009].
11. Sertznig P, Reichrath J. Peroxisome proliferator-activated receptors (PPARs) in dermatology: Challenge and promise. Dermatoendocrinol 2011; 3: 130-5.
12. Davidovici BB, Sattar N, Prinz JC, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010; 130: 1785-96.
13. Terauchi Y. PPARgamma and metabolic syndrome. Rinsho Byori 2007; 55: 447-51.
14. Osella-Abate S, Zaccagna A, Savoia P, Quaglino P, Salomone B, Bernengo MG. Expression of apoptosis markers on peripheral blood lymphocytes from patients with cutaneous T-cell lymphoma during extracorporeal photochemotherapy. J Am Acad Dermatol 2001; 44: 40-7.
15. Jo SH, Yang C, Miao Q, et al. Peroxisome proliferator-activated receptor γ promotes lymphocyte survival through its actions on cellular metabolic activities. J Immunol 2006; 177: 3737-45.
16. Sabat R, Philipp S, Höflich C, et al. Immunopathogenesis of psoriasis. Exp Dermatol 2007; 16: 779-98.
17. Nakajima H, Nakajima K, Tarutani M, Morishige R, Sano S. Kinetics of circulating Th17 cytokines and adipokines in psoriasis patients. Arch Dermatol Res 2011; 303: 451-5.
18. Hwang ES. Transcriptional regulation of T helper 17 cell differentiation. Yonsei Med J 2010; 51: 484-91.
19. Griffiths CEM, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-71.
20. Cao Y. Angiogenesis modulates adipogenesis and obesity. J Clin Invest 2007; 117: 2362-8.
21. Kim KY, Ahn JH, Cheon HG. Anti-angiogenic action of PPARγ ligand in human umbilical vein endothelial cells is mediated by PTEN upregulation and VEGFR-2 downregulation. Mol Cell Biochem 2011; 358: 375-85.
22. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Int Med 2007; 167: 1670-5.
23. Gustafson B, Hammarstedt A, Andersson CX, Smith U. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27: 2276-83.
24. Yang XY, Wang LH, Chen T, et al. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Chem 2000; 275: 4541-4.
25. Hamminga EA, van der Lely AJ, Neumann HA, Thio HB. Chronic inflammation in psoriasis and obesity: implications for therapy. Med Hypotheses 2006; 67: 768-73.
26. Tekin NS, Tekin IO, Barut F, Sipahi EY. Accumulation of oxidized low density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediators Inflam 2007; 2007: 1-5.
27. Fuenzalida K, Quintanilla R, Ramos P, et al. Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 antiapoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis. J Biol Chem 2007; 282: 37006-15.
28. Shibata S, Saeki H, Tada Y, Karakawa M, Komine M, Tamaki K. Serum high molecular weight adiponectin levels are decreased in psoriasis patients. J Dermatol Sci 2009; 55: 62-3.
29. Marsushita K, Tamakoshi K, Yatsuya H, et al. Further inflammatory information on metabolic syndrome by adiponectin evaluation. Int J Cardiol 2008; 124: 339-44.
30. Alsaleh A, Sanders TA, O'Dell SD. Effect of interaction between PPARG, PPARA and ADIPOQ gene variants and dietary fatty acids on plasma lipid profile and adiponectin concentration in a large intervention study. Proc Nutr Soc 2012; 71: 141-53.
31. Krentz AJ, Friedmann PS. Type 2 diabetes, psoriasis and thiazolidinediones. Int J Clin Pract 2006; 60: 362-3.
32. Itoh H, Doi K, Tanaka T, et al. Hypertension and insulin resistance: role of peroxisome proliferator-activated receptor gamma. Clin Exp Pharmacol Physiol 1999; 26: 558-60.
33. Demerjian M, Man MQ, Choi EH, et al. Topical treatment with thiazolidinediones, activators of peroxisome proliferator-activated receptor-gamma, normalizes epidermal homeostasis in a murine hyperproliferative disease model. Exp Dermatol 2006; 15: 154-60.
34. Komers R, Vrána A. Thiazolidinediones-tools for the research of metabolic syndrome X. Physiol Res 1998; 47: 215-25.
35. Kuk JL, Ardern CI. Age and sex differences in the clustering of metabolic syndrome factors: association with mortality risk. Diabetes Care 2010; 33: 2457-61.
36. Okura T, Nakamura M, Takata Y, Watanabe S, Kitami Y, Hiwada K. Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells. Eur J Pharmacol 2000; 407: 227-35.
37. Nijsten T, Geluyckens E, Colpaert C, Lambert J. peroxisome proliferator-activated receptors in squamous cell carcinoma and its precursors. J Cutan Pathol 2005; 32: 340-7.
38. Schmuth M, Jiang YJ, Dubrac S, Elias PM, Feingold KR. Thematic review series: skin lipids. Peroxisome proliferator-activated receptors and liver X receptors in epidermal biology. J Lipid Res 2008; 49: 499-509.
39. Tan X, Dagher H, Hutton CA, Bourke JE. Effects of PPAR gamma ligands on TGF-b1-induced epithelial-mesenchymal transition in alveolar epithelial cells. Respiratory Research 2010; 11: 21.
40. Burgermeister E, Chuderland D, Hanoch T, Meyer M, Liscovitch M, Seger R. Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor γ. Molecular and Cellular Biology 2007; 27(3): 803-17.
41. Burgermeister E, Seger R. MAPK kinases as nucleo-cytoplasmic shuttles for PPARgamma. Cell Cycle 2007; 6: 1539-48.